PR NEWSWIRE

Previous Stories

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Jan 28 2022 - PR NewsWire

Lonza to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art…


Appendix 4C – Q2 FY22 Quarterly Cash Flow Report

Jan 27 2022 - PR NewsWire

Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications…


CRRC Delivers Four Additional Second-Generation SDA1 Locomotives to SCT Logistics in Australia

Jan 26 2022 - PR NewsWire

MELBOURNE, Australia, Jan. 26, 2022 /PRNewswire/ — CRRC Corporation Limited ("CRRC", 1766.HK) announced that four additional second-generation SDA1 Locomotives have shipped…


ChannelAdvisor Achieves New Milestone to Help Fuel Global E-Commerce Growth for Brands

Jan 26 2022 - PR NewsWire

Leading multichannel commerce platform now offers over 300 global marketplace and retailer integrations MELBOURNE, Australia, Jan. 26, 2022 /PRNewswire/ — ChannelAdvisor Corporation…


KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP’S GLOBAL HEALTHCARE ‘OPEN HOUSE’ VIRTUAL CONFERENCE

Jan 26 2022 - PR NewsWire

SYDNEY, Jan. 25, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased…


ECINS Launches Australia Community Support Program Awarding $500,000 (AUD) in Free Services & Subscriptions to Indigenous Organisations and Educational Inst

Jan 21 2022 - PR NewsWire

>> ECINS Australia Offers Collaborative Case Management Software to Empower Indigenous Organisations & Educational Institutions to Streamline Processes in Order…


Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an orally bioavailable Chimeric Degrader targeting Androgen Receptor for Prostate Can

Jan 21 2022 - PR NewsWire

MELBOURNE, Australia, Jan. 21, 2022 /PRNewswire/ – Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers…


Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Can

Jan 20 2022 - PR NewsWire

MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ – Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers…


Infosys Recognized as Global Top Employer for the Second Consecutive Year; Ranked #1 in India Again

Jan 20 2022 - PR NewsWire

Awarded Top Employer Certification in 22 Countries, Ranked among Top 3 Employers in Asia Pacific, Middle East, and North America…


Aboriginal Male Healing Centre’s Holistic Approach Breaks Cycle of Domestic Violence with Data-driven Case Management Solution Built in Western Australia

Jan 20 2022 - PR NewsWire

>> ECINS works with Centre to custom build new client engagement module to establish rehabilitation program for domestic violence offenders…


Analyse The Market From A Different Angle